Super User
Product Insert
Tildren®
(tiludronate disodium)
BISPHOSPHONATE DRUG FOR INTRAVENOUS INFUSION.
For use in horses only
WARNINGS
Do not use in horses intended for human consumption.
NSAIDs should not be used concurrently with Tildren®. Concurrent use of NSAIDs with Tildren® may increase the risk of renal toxicity and acute renal failure.
HUMAN WARNINGS
Not for human use. Keep this and all drugs out of the reach of children. Consult a physician in case of accidental human exposure.
CAUTION
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
INDICATION
Tildren® is indicated for the control of clinical signs associated with navicular syndrome in horses.
CONTRAINDICATIONS
Do not use in horses with known hypersensitivity to tiludronate disodium or to mannitol. Do not use in horses with impaired renal function or with a history of renal disease. Bisphosphonates are excreted by the kidney; therefore, conditions causing renal impairment may increase plasma bisphosphonate concentrations resulting in an increased risk for adverse reactions.
PRECAUTIONS
Approximately 30-45% of horses administered Tildren® will demonstrate transient signs consistent with abdominal pain (colic). Horses should be observed closely for 4 hours post-infusion for the development of clinical signs consistent with colic or other adverse reactions. Colic signs can last approximately 90 minutes and may be intermittent in nature. Hand walking the horse may improve or resolve the colic signs in many cases. If a horse requires medical therapy, non-NSAID treatments should be administered due to the risk for renal toxicity. Avoid NSAID use.
Horses should be well hydrated prior to administration of Tildren® due to the potential nephrotoxic effects of Tildren®.
Tildren® should be used with caution in horses receiving concurrent administration of other drugs that may reduce serum calcium (such as tetracyclines) or whose toxicity may exacerbate a reduction in serum calcium (such as aminoglycosides).
Horses with HYPP (heterozygous or homozygous) may be at an increased risk for adverse reactions, including colic signs, hyperkalemic episodes, and death.
The safe use of Tildren® has not been evaluated in horses less than 4 years of age.
Bisphosphonates should not be used in pregnant or lactating mares, or mares intended for breeding. Bisphosphonates have been shown to cause fetal developmental abnormalities in laboratory animals.
DOSAGE AND ADMINISTRATION
A single dose of Tildren® should be administered as an intravenous infusion at a dose of 1 mg/kg (0.45 mg/ lb). The infusion should be administered slowly and evenly over 90 minutes to minimize the risk of adverse reactions. Maximum effect may not occur until 2 months post-treatment.
For ADMINISTRATION INSTRUCTIONS (preparation of the reconstituted solution (20mg/mL) and preparation of the solution for infusion) and for complete product information, please read the insert contained within the product packaging.
STORAGE
Sterile powder (not reconstituted): Store at controlled room temperature 68°F-77°F (20°C-25°C). After preparation, the infusion should be administered either within 2 hours of preparation, or it can be stored for up to 24 hours under refrigeration at 36°F-46° F (2°C-8°C) and protected from light.
HOW SUPPLIED
Tildren® is supplied in a 30mL glass vial as a white, sterile lyophilized powder containing 500mg tiludronic acid (as tiludronate disodium) packaged in a folding carton. For technical assistance or to report suspected adverse reactions, call 1-888-524-6332.
INFORMATION FOR OWNERS
Prior to Tildren® administration, owners should be advised of the potential for adverse reactions in the hours or days following treatment. Adverse reactions within 4 hours post dosing may include signs of colic (manifested as pawing, stretching, getting up and down, sweating, rolling, looking at flanks, kicking at belly, frequent gas, and pacing). Owners should be instructed to contact their veterinarian immediately if any adverse reactions are observed. Owners should be advised to consult with their veterinarian prior to the administration of an NSAID following Tildren® administration.
Made in Canada
Patent information: U.S. patent 6,057,306
Tildren Studies
Injectable Bisphosphonates in the Treatment of Postmenopausal Osteoporosis
Human Pharmacokinetics of Tiludronate
Tiludronate: Bone Pharmacology and Safety
TILDREN - tiludronate disodium powder, for solution Ceva Sante Animale
Pharmacological effects of tiludronate in horses after long-term immobilization
Stability and Sterility of Tildren® (tiludronate disodium) Post-Reconstitution
TILUDRONATE - Bibliography May 2016
TILUDRONATE - Bibliography Synopsis May 2016
Freedom of Information Summary - Original New Animal Drug Application
Get in Touch
Questions? Call us at 1-888-524-6332 or email us at This email address is being protected from spambots. You need JavaScript enabled to view it.
Bimeda US Office
Equine Sales Representatives
Amy Bell
West
This email address is being protected from spambots. You need JavaScript enabled to view it.
Mark Glassford
South
This email address is being protected from spambots. You need JavaScript enabled to view it.
Rory Boren
Central
This email address is being protected from spambots. You need JavaScript enabled to view it.
Jim Conway
Southeast
This email address is being protected from spambots. You need JavaScript enabled to view it.
Archie McNeil
Northeast
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tildren and Tiludronic Acid: A Clinical Update
Read Dr. Allen's recent presentation called "Tildren® and Tiludronic Acid: A Clinical Update" from the AAEP Annual Conference in San Antonio, Texas, USA on November 17-21, 2017.
Legal Notice
I - Legal Notice for the website www.tildren.us
This site (hereinafter the "Site") is authored by:
Bimeda U.S. HOLDINGS, INC. (“Bimeda”)
One Tower Lane, Suite 2250
Oakbrook Terrace, IL 60181 USA
Tel: 1 888 524 6332
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
This Site is hosted and created by ProbaseWeb (www.probaseweb.com)
The use of the Site is governed by these terms and conditions of use.
By accessing the Site, the Internet user agrees to comply with and respect the terms of use defined below. The Internet user acknowledges having read, understood and accepted these usage conditions in their entirety. If the Internet user refuses any of these usage conditions, that user is requested and constrained not to navigate through the Site.
II - Terms and conditions of use of the Site www.tildren.us
A. Content and Access to the Site
Content of the Site
Bimeda endeavors to update the contents of the Site and to deliver correct information to the Internet user. Nonetheless, Bimeda shall not be held responsible for any possible errors and/or omissions.
Bimeda reserves all rights to modify, terminate, suspend or interrupt any or all of the Site's services or contents without prior warning. The Internet user may signal any error or omission to the following email address: This email address is being protected from spambots. You need JavaScript enabled to view it.
Any usage of the Site not conforming to its original intent and any violation of these terms and conditions may result in the application of criminal and civil penalties provided for by law.
Access to the Site
Access to the services is made through a personal computer connected to a telecommunications network enabling access to the Site in accordance with the communications protocols commonly employed on the Internet.
Bimeda endeavors to maintain accessibility to the Site 24 hours a day, 7 days a week, but without incurring any obligation to effectively deliver as such.
For maintenance purposes, updates, and any other reason, specifically of a technical nature, access to the Site may be occasionally interrupted.
In no event shall Bimeda be held responsible for these interruptions or for any consequences that may thereby ensue for the Internet user.
In addition, Bimeda shall not be held responsible for the existence of any malware on the Site or for any consequences that may thereby ensue for the Internet user.
Hypertext links placed on the Site
The Site may contain hypertext links to other sites that are not managed and/or not authored by Bimeda.
In no manner whatsoever does Bimeda exercise any control over the information, products or services offered by such linked sites and may in no circumstances be held responsible for the contents of any such sites.
Accessing such sites by the Internet user is the sole responsibility of the user and is done at user's own risk.
B. Intellectual Property
Registered Trademarks
Trademarks featured on the Site are either the property of Bimeda, its parent company Bimeda Sante Animale S.A., one of its subsidiaries, or of brands belonging to third parties who have authorized usage of such trademarks by Bimeda and/or its parent company or subsidiaries.
Access to the Site grants no other rights other than viewing the Site's contents.
The publishing of this Site on the Internet does not derogate any usage license of the trademarks cited, as any such usage is dependent on the express, prior, written authorization of the trademark owner(s).
Author's rights / Copyright / Trademarks and designs / Patents
The Site is an intellectual work protected by the rights of intellectual property.
All elements of the Site are the exclusive property of Bimeda and/or its parent company, being the only bodies authorized to exercise the relevant intellectual property and personality rights. The Internet user does not acquire any license or any other right other than that of consulting the Site.
The Site and its constituent components are protected by laws of the USA and international legal conventions relative to respecting author's rights, copyrights, designs and trademarks and patents.
The reproduction and/or representation of any aspect of the Site is strictly limited to the private use of the individual’s viewing of the site.
All requests for authorization must be addressed to the following email address: This email address is being protected from spambots. You need JavaScript enabled to view it.
C. Personal data
Treatment of personal data
Bimeda may request the Internet user to provide personally identifying data (name, address, email address, profession, etc.).
The Internet user retains the rights to access, correct or delete any such personal data.
To exercise this right, the Internet user is requested to address a letter to the following address: This email address is being protected from spambots. You need JavaScript enabled to view it.
The modification or deletion will be executed as soon as possible upon receipt of the request.
Certain information not corresponding to personal data and not enabling the identification of the Internet user may be recorded by the servers used by Bimeda (browser used, IP address, etc.).
The Internet user is hereby informed that a cookie may be automatically installed in the user's browser upon visiting the Site.
The cookie is a block of data that does not enable identification of the Internet user but which serves to record information relative to the user's navigation within the site (the pages that have been visited, the date and time of visiting, etc.).
The use of cookies is intended to permit analyses of site visit frequencies, audience measurements etc. with the intent of improving the Site's quality.
Your browser typically contains an option enabling cookies to be refused. This does not prevent connection to our Site, but may negatively affect the Site's performance.
The collection of personal information identifying the Internet user is intended for use by Bimeda; however, such information may be transmitted by Bimeda to third parties, most notably to other companies belonging to the Bimeda Group. The Internet user can present their opposition to this transmission by addressing an email to the following address: This email address is being protected from spambots. You need JavaScript enabled to view it.
Security
Bimeda applies technical and organizational security techniques in order to protect the data that it manages against accidental and intentional manipulation, against the loss or destruction of the data, and against the access to this data by unauthorized persons.
These security measures are constantly being improved in correlation with technological developments.
For all information requests, suggestions or claims relating to the treatment of personal data concerning the individual Internet user, that user should directly address their concerns to This email address is being protected from spambots. You need JavaScript enabled to view it.
D. Responsibility
It is forbidden: to use the Site or communication services to forward chain mail, "junk mail", "spam" or any repetitive or unsolicited mail (commercial or otherwise); to harvest or collect, in any manner whatsoever, information relating to third parties, notably email addresses, without the agreement of the third parties concerned; to create or exploit false identities, to falsify an email address or header, or attempt to mislead third parties in any manner whatsoever as to the identity of the message sender or as to the origin of the message; to forward any inappropriate content such as is defined and referenced below under "Inappropriate Content"; to forward any element containing a virus or other component that is harmful or detrimental to the Site or to third parties or in contravention of the law; to attempt to access the offered services in an unauthorized manner of other accounts, information systems or networks connected to the Site services through the usage of various passwords or by any other means; or to interfere with the use and enjoyment of the service by any other Internet user or with the use and enjoyment of similar services by the means of another entity.
Inappropriate Content includes any language, comments, remarks and images considered by Bimeda as being obscene, deceptive, illegal, racist, defamatory or conducive to harassment, violating third party rights or restraining and/or preventing the use of other Internet users of the forums or chat rooms accessible through the Site.
The use of the Site, its services and any element or information obtained through it, is the exclusive responsibility of the Internet user.
Bimeda does not provide the Internet user with any guarantee of any sort, express or implied, as to the quality of the Site's services or their commercial quality, consistency, or to research results that meet the Internet user's expectations, and refuses all responsibilities as regards possible disputes, actions or recourse by third parties who might wish to lay claim to their rights, notably private rights, over any content not created by Bimeda.
In addition, Bimeda shall not be held responsible for: any lack of performance of the Site and/or any software used or downloaded from the Site; any loss of data or services resulting from delays, modifications, suspensions or interruptions to its services; inaccuracy, poor quality or the very nature of the information obtained through its services; any consequences deriving directly or indirectly from the transmission of malware through its servers; nor for any manipulation by any unauthorized persons of data on the Site or of data pertaining to the Internet user.
Bimeda shall likewise not be held responsible for any direct or indirect damages, notably but not exclusively including loss of profits, clientele, or data, all intangible benefits, loss of opportunity for income or any other loss or damages possibly arising from the use or, on the contrary, non-use caused by inaccessibility of the Site.
As regards Personal Content, such as is defined below, supplied by Internet users, Bimeda declines all responsibility relating to the existence of such content in chat rooms or in any other discussion service.
Such Personal Content, be it opinions, declarations, recommendations or points of view, is representative uniquely of the opinions, declarations, recommendations and points of view of the Users and never expressly nor implicitly those of Bimeda.
The Site may contain links to other sites that are not managed and/or not authored by Bimeda.
In no manner whatsoever does Bimeda exercise any control over the information, products or services offered by such linked sites and may in no circumstances be held responsible for the contents of any such sites.
The Internet user agrees to indemnify and defend Bimeda against any and all claims, damages, losses, costs, including without limitation, loss of income, or loss of data, whether direct or indirect arising from any violation by the Internet user of any of the conditions of this legal notice.
E. Applicable law – Jurisdiction
This Site and its contents, as with these Site terms and conditions, are governed by the laws of the USA.
Any litigation related to this Site and its use shall be brought before the federal courts of the USA.
In the event that any of these measures described in these terms and conditions shall be declared null or void, such measures shall be interpreted in a manner so as to best reflect the original intentions of Bimeda and all other measures shall remain considered as legally valid and legally enforceable.
The non-application or absence of an applicable claim by Bimeda for any one of the measures in these terms and conditions or of any other right shall in no case be deemed as a relinquishment by Bimeda of such measures or rights unless such relinquishment is explicitly granted in writing.
F. Modification of these terms and conditions of use
Bimeda reserves all rights to modify at any time and without consent or notice any or all of these Site terms and conditions of use, specifically as regards any new regulatory or legislative actions or any efforts made to improve usage of the Site by the Internet user.
Any future modification to usage of the Site shall be included within these terms and conditions.
Trademark and Copyright Notice
©2017 Bimeda Holdings PLC. All Rights Reserved.
All materials contained on this website are subject to the ownership rights of Bimeda Holdings PLC or its affiliates (“Bimeda”). Bimeda hereby authorizes you to make a single copy of the content herein for your use in learning about or evaluating Bimeda's products. You agree that any copy made must include Bimeda's copyright notice. No other permission is granted to you to print, copy, reproduce, distribute, transmit, upload, download, store, display in public, alter, or modify the content contained on this website.
All trademarks are registered or unregistered trademarks of Bimeda Holdings PLC or one of its affiliates in the United States and are protected under the trademark laws of the United States and certain foreign jurisdictions. Marks of third parties may appear on this Site to refer to those companies' goods and services and are the property of their respective owners.
Nothing contained on this website should be construed as granting any license or right to use any mark displayed on this website without the written permission of Bimeda or such third party that may own the marks displayed on this website. Use of such marks without written permission is strictly prohibited.
How it works
Learn More About How Tildren® Works
- Tildren® binds preferentially to the mineral phase of the bone at remodeling sites.
- Acidification breaks the bond.
- Tildren® is taken into the osteoclast by endocytosis.
See Tildren® at Work
In navicular syndrome, excessive mechanical stress results in bone resorption outpacing bone formation.
Tildren® (tiludronate disodium) restores balance to the process of bone remodeling by partially inhibiting bone resorption by:
- Modulating excessive osteoclastic activity
- Not modifying osteoblastic activity
- Slowing the rate of bone turnover
By modulating excessive osteoclastic activity, bone remodeling can normalize.
The Proven Effectiveness of Tildren®
The active ingredient in Tildren® is tiludronate disodium, a bisphosphonate that regulates osteoclasts in areas of excessive activity.
- Tildren® is administered via intravenous infusion over a 90-minute period, quickly binding to the mineral matrix of the bone.
- The acidity of the remodeling environment releases Tildren® from the bone matrix, where it is then taken into the osteoclast.
- Once inside, Tildren® inhibits the bone re-absorption process and kills off excess osteoclasts.
Safe and Long-lasting Relief
A single 500 mg vial treats horses up to 1,210 lb.
Controlled administration – Reconstituted with 0.9% sodium chloride solution and administered through intravenous infusion over the course of 90 minutes.
Safe – Limited and transient side effects when used according to label.
Long-lasting relief – A single treatment lasts up to six months.
1 Freedom of Information Summary. NADA #141-420. Approved February 13, 2014.
In conjunction with corrective shoeing, Tildren® has been proven to be more effective in controlling the clinical signs of navicular syndrome than corrective shoeing alone.1
Treatment with Tildren
Product Safety
In a controlled 6-month open use field study1, Tildren® (tiludronate disodium) was evaluated under strict conditions. Horses were observed for four hours following infusion and adverse events were recorded.
The most common observations were clinical signs associated with colic, which are defined as outlined below. While colic may occur, clinical signs and incidence vary and may be intermittent.
Clinical signs that were considered to be indicative of colic:
Pawing, getting up and down, pacing, restlessness, rolling, trying to roll, looking or biting at side, stretching out/straining, kicking at belly/walls, repeatedly shifting weight behind.
1 Freedom of Information Summary. NADA #141-420. Approved February 13, 2014.
TILUDRONATE, Bibliography May 2016, Studies: 2003 to 2016, Source: PubMed
A Statement From Dr. Dave Ellefson Regarding Bisphosphonate Use
Dosing and Administration
Tildren® is administered through a single intravenous infusion of 1mg/kg (0.45mg/lb) in 0.9% Sodium Chloride, and is given slowly and evenly over 90 minutes. Of the administered dose, 30-50% of the tiludronate disodium distributes to the bone within 12 hours of dosing.
Bone concentrations are higher than plasma concentrations as early as 12 hours post-administration. The drug is slowly, but continuously, released in relation to the bone remodeling process and concentrations are still present at 6 months, but lower than at 3 months, in the bone.
About Navicular Syndrome
Cause for Pain
Horses suffering from navicular syndrome feel pain in the palmar, or heel, region of the foot. They show gait abnormalities associated with degenerative lesions of the navicular bone.
Clinical Signs and Diagnosis
Clinical signs associated with navicular syndrome can vary but are typically indicated by a gait change or lameness which is aggravated when walking on hard ground or trotting circles.
If you suspect your horse may have navicular syndrome, please contact your veterinarian.
To diagnose navicular syndrome, the following methods may be used:
Podcast: Navicular Syndrome Update
From initial diagnosis to hoof care and bisphosphonate use, find out the newest information about this debilitating condition.
Recorded at Ask TheHorse Live